ReNAgade Therapeutics

ReNAgade developed proprietary all-RNA therapeutic platforms combining advanced lipid nanoparticle (LNP) delivery systems with comprehensive capabilities in coding RNAs, genome editing RNAs, and gene insertion. The company demonstrated industry-leading extra-hepatic tissue targeting in non-human primate models. In May 2024 it was acquired by Orna Therapeutics to create a leading circular RNA medicines company. The combined entity has robust financing ($300M+ Series A for ReNAgade alone), an expanded R&D engine focused on oncology/autoimmune panCAR therapies, genetic disease programs, and vaccine collaborations with Merck. No clinical results have been published yet—programs are largely preclinical or IND-enabling.